Engineered immune cells take on glioblastoma in early trial

NCT ID NCT05660369

Recruiting now Disease control Sponsor: Marcela V. Maus, M.D.,Ph.D. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a serious brain cancer that has come back. The treatment uses a patient's own immune cells that are modified in a lab to better recognize and attack the cancer. The main goal is to find a safe dose and check for side effects in about 21 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CARv3-TEAM-E T cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for glioblastoma, a tough brain cancer.
What could go wrong: This is a very early Phase 1 trial with only 21 people, so it is mainly checking safety, not yet proving it works. There is a risk of serious side effects from the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain glioma glioblastoma glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MALIGNANT GLIOMA RECURRENT GLIOBLASTOMA RECURRENT GLIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02215, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.